alzheon, Author at Alzheon | Preserving Future Memories - Page 6 of 21

About alzheon

This author has not yet filled in any details.
So far alzheon has created 204 blog entries.

15 Feb, 2023

I interview Dr. Martin Tolar, Founder, CEO and President of Alzheon on the Phase 3 trial going on right now

alzheon2023-02-16T12:37:20-05:00February 15th, 2023|

20 Jan, 2023

Biotech and Business Development Leader Wendy Nelson on Living With the APOE4 Gene

alzheon2023-01-20T11:31:56-05:00January 20th, 2023|

6 Dec, 2022

Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Clinical Trial Evaluating Oral ALZ-801 (Valiltramiprosate) in APOE4/4 Homozygotes with Early Alzheimer’s Disease

alzheon2024-08-26T10:56:30-04:00December 6th, 2022|

22 Nov, 2022

Alzheon to Present Industry-Leading Biomarker, Brain Preservation, and Clinical Effects with Oral ALZ-801 (Valiltramiprosate) at 15th Annual Clinical Trials in Alzheimer’s Disease Conference

alzheon2024-08-12T09:59:56-04:00November 22nd, 2022|

12 Oct, 2022

Alzheon’s Pill For Alzheimer’s Recruits for Clinical Trials

alzheon2022-11-07T18:32:37-05:00October 12th, 2022|

20 Sep, 2022

Alzheon Biomarker Trial Brings Insight to Stalled Treatment Space

alzheon2022-10-02T16:55:56-04:00September 20th, 2022|

20 Sep, 2022

Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Effects Following 12 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease

alzheon2024-08-05T20:01:25-04:00September 20th, 2022|

20 Sep, 2022

Alzheon Appoints Glenn Pauly as Head of Commercial

alzheon2024-08-05T19:22:39-04:00September 20th, 2022|

26 Jul, 2022

Alzheon to Present Industry-Leading Phase 2 Biomarker and Clinical Data with ALZ-801 (Valiltramiprosate) Oral Tablet at 2022 Alzheimer’s Association International Conference

alzheon2024-08-12T10:03:18-04:00July 26th, 2022|

7 Jun, 2022

Alzheon to Present ALZ-801 (Valiltramiprosate) Oral Tablet Program Update as Potential Treatment for Alzheimer’s Disease in Adults with Down Syndrome at 4th International Trisomy 21 Research Conference

alzheon2024-08-12T09:18:21-04:00June 7th, 2022|